PT - JOURNAL ARTICLE AU - Rosadiño, John Danvic T. AU - Pagtakhan, Ronivin G. AU - Briñes, Matthew T. AU - Dinglasan, Jeanno Lorenz G. AU - Cruz, Denis P. AU - Corciega, John Oliver L. AU - Pagtakhan, Aeronne B. AU - Regencia, Zypher Jude G. AU - Baja, Emmanuel S. TI - Implementation of Unassisted and Community-Based HIV Self-Testing (HIVST) during the COVID-19 pandemic among Men-who-have-sex-with-Men (MSM) and Transgender Women (TGW): A Demonstration Study in Metro Manila, Philippines AID - 10.1101/2021.11.13.21266310 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.13.21266310 4099 - http://medrxiv.org/content/early/2021/11/14/2021.11.13.21266310.short 4100 - http://medrxiv.org/content/early/2021/11/14/2021.11.13.21266310.full AB - Objective The study aimed to demonstrate the feasibility of an unassisted and community-based HIV self-testing (HIVST) distribution model and to evaluate its acceptability among men-having-sex-with-men (MSM) and transgender women (TGW).Methods Our observational study focused on implementing the HIVST service in Metro Manila, Philippines. Convenience sampling was done with the following inclusion criteria: MSM or TGW, at least 18 years old, and had no previous HIV diagnosis. Individuals taking HIV Pre-exposure Prophylaxis (PrEP), on Antiretroviral Therapy (ART), or female sex at birth were excluded. The implementation of the study was online using a virtual assistant and delivery system via courier due to COVID-19-related lockdowns. Feasibility was measured by the number of HIVST kits successfully delivered and utilized and the HIV point prevalence rate. Moreover, acceptability was evaluated by a 10-item system usability scale (SUS). HIV prevalence was estimated with linkage to care prioritized for reactive participants.Results Out of 1,690 kits distributed, only 953 (56.4%) participants reported their results. Overall HIV point prevalence was 9.8%, with 56 (60.2%) reactive participants linked to further testing. Furthermore, 27.4% of respondents self-reported, and 13.4% of the reactive participants were first-time testers. The HIVST service had an overall mean ± standard deviation SUS score of 81.0 ± 13.0, rendering the HIVST kits very acceptable.Conclusions HIVST is acceptable and feasible to MSM and TGW. Online platforms are an innovative and effective way to deliver HIVST service during a pandemic. However, messaging to entice people to use the kit must be differentiated based on their age, gender identity and expression, and previous HIVST experience to offer the service efficiently to the target populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded and supported by Global Fund Sustainability of HIV Services for Key Populations in Asia Program (SKPA Philippines), AIDS Healthcare Foundation Philippines, Pilipinas Shell Foundation, Inc. (PSFI), World Health Organization Representative Office for the Philippines, Joint United Nations Programme on HIV and AIDS Philippines Country Office, Chembio Diagnostic Systems, Inc. Its contents are solely the responsibility of the authors and do not necessarily represent the official position of the funding agencies. The funders were not involved in the preparation of this journal article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of the Philippines Manila Research Ethics Board (UPMREB) has approved the ethical clearance of this study with UPMREB CODE: 2019-474-01. All data were treated following the Philippine Data Privacy Act of 2012 (Republic Act 10173).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed are not publicly available due to the risk of identifying individual participants.